<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35015">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736020</url>
  </required_header>
  <id_info>
    <org_study_id>MIRB 1007, UCI 2004-3707</org_study_id>
    <secondary_id>R34MH087390</secondary_id>
    <nct_id>NCT01736020</nct_id>
  </id_info>
  <brief_title>Developing Anesthesia as Post Traumatic Stress Disorder (PTSD) Therapy</brief_title>
  <official_title>Developing Anesthesia as PTSD Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This preclinical phase 1 development study in healthy volunteers seeks to identify if low
      doses of commonly used non-triggering anesthetic agents might have clinical utility for
      modulating emotional memory processing and to understand the nature of the brain mechanisms
      of drug action.  Optimally, a drug, dose and brain mechanism of action will be identified
      that will form the foundation for future use in clinical studies of patients with PTSD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of events remembered</measure>
    <time_frame>Day 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of items remembered in long-term memory 4 days after viewing emotional or neutral pictures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-related fMRI BOLD signals</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evoked fMRI responses to emotional and neutral pictures are measured and later correlated with subsequent memory performance.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tolerability</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjective and objective measures of subject responses to the various agents are noted.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">315</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine intravenous infusion during scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol intravenous infusion during scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine intravenous infusion during scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitrous Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitrous Oxide inhalation during scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrous Oxide</intervention_name>
    <description>A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.</description>
    <arm_group_label>Nitrous Oxide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults.

          -  Between the ages of 18 and 35.

        Exclusion Criteria:

          -  Pregnancy.

          -  Left-handed.

          -  Unusual facial anatomy.

          -  History of esophageal reflux.

          -  Respiratory problems.

          -  Central nervous system disorders.

          -  Cardiovascular problems.

          -  Kidney disease.

          -  Diabetes.

          -  History of Substance abuse.

          -  History of adverse anesthetic reactions.

          -  Hepatitis.

          -  Failure to pass MRI screening questionnaire.

          -  Fear of small-enclosed spaces.

          -  Mental illness.

          -  Non-native English speakers.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael T Alkire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine and Long Beach VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael T Alkire, MD</last_name>
    <phone>949 824 6128</phone>
    <email>malkire@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiroki Hayama, PhD</last_name>
    <phone>949 824 6128</phone>
    <email>hhayama@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael T Alkire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 27, 2012</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Michael Alkire</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Nitrous Oxide</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
